Express Scripts was the first to cap out-of-pocket costs for insulin medications at $25 for a 30-day supply in 2019, well before the government took action "The fact is that in the unlikely event the ...

Express Scripts is suing the Federal Trade Commission (FTC), demanding the retraction of a report it claims is false and harmful to the pharmacy benefit manager (PBM) industry. Express Scripts is ...

ST. LOUIS (CN) — Express Scripts filed a federal lawsuit against the Federal Trade Commission on Tuesday, claiming its report blaming the pharmacy benefit management industry for rising drug costs was ...

Cigna is following through on promises to more aggressively defend its pharmacy benefit manager. On Tuesday, the healthcare company’s PBM, Express Scripts, sued the Federal Trade Commission over the ...

Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and demanded the agency retract a report saying the industry middlemen ...

The Federal Trade Commission is targeting the three largest pharmacy benefit managers over rebate schemes that allegedly inflate insulin prices for some consumers. “This perverse system results in ...

Express Scripts, Caremark and OptumRx are suing the Federal Trade Commission for trying to "upend present day drug rebate contracts." The lawsuit was filed Tuesday, Nov. 19 in federal court in ...

Amid increased scrutiny from policymakers, the pharmacy benefit manager (PBM) industry is now looking to strike back through legal channels. Express Scripts, one of the biggest PBMs in the U.S., ...

Pharmacy benefit manager Express Scripts is fighting back against the ongoing Federal Trade Commission investigation into its industry's business practices. The Cigna division filed a lawsuit Tuesday ...

NEW YORK, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts sued the U.S. Federal Trade Commission on Tuesday over the regulator's recent drug pricing report, calling the report's ...

FTC's July 2024 report makes unsubstantiated, false and biased claims about the PBM industry; fails to take into account the value that PBMs deliver to consumers and patients ST. LOUIS, Sept. 17, 2024 ...

FTC's July 2024 report makes unsubstantiated, false and biased claims about the PBM industry; fails to take into account the value that PBMs deliver to consumers and patients Information about Express ...